Introduction, background and rationale
When the results of ASCOT are known we may be faced with two problems: firstly a lack of insight into the mechanisms which might underlie differences in outcome on beta-blocker or calcium channel blocker based treatment. Secondly, if statins are shown to be effective in reducing coronary risk in patients with 'UK average' cholesterol in the lipidlowering limb of ASCOT, the health care cost of treating all high risk hypertensives with statins may not be affordable within national health care budgets.
Patients who have already had a myocardial infarct can have their cardiovascular risk stratified according to the sensitivity of their baroreflex, which predicts outcome. In such secondary prevention, however, there is good evidence that all patients should be treated with lipid-lowering drugs regardless of starting levels.
In primary prevention, however, the cost-benefit balance of lipid lowering will be very different, and some means of predicting risk in those already known to be at increased risk by established risk factors is needed in order to enable limited resources to be targeted on the most endangered patients.
Baroreflex function predicts outcome after myocardial infarction (MI) [1] [2] [3] [4] Depressed baroreflex sensitivity is a stronger predictor of arrhythmic events in post-myocardial infarct patients (relative risk 23.1, 95% CI 7.7 to 69.2) than left ventricular function (RR 10.4, 95% CI 3.3 to 32.6) or heart rate variability (RR 10.1, 95% CI 5.6 to 18.1), when tested by the Oxford phenylephrine method, and is safe even in the immediate post-infarction period. 3 The results of the large prospective multicentre ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) study 4 show that baroreflex sensitivity measurement post-MI can add to conventional predictors, such as left ventricular ejection fraction and ventricular ectopy and so identify a group at approximately tripled risk, particularly in patients aged Ͻ65 years.
Baroreceptor reflexes buffer changes in blood pressure and cardiac output, and so may well protect the heart directly, but their transduction mechanism depends on the distensibility of elastic vessels in the aorta and aortic arch and so may reflect vascular compliance. Calcium channel blockers and beta-blockers have opposite effects on vascular compliance, and so it would be of considerable interest to test baroreflex sensitivity in a sub-study of ASCOT.
There has been no prospective outcome trial of baroreflex function and autonomic tone in patients with essential hypertension.
Measurements of these potential predictors of out-come, combined with established risk predictors such as measurements of echocardiographic left ventricular function, and fibrinogen levels in the same group of patients then followed for 5 to 6 years would give data on the comparative usefulness of several methods. It may be, of course, that one method is an adequate surrogate for some of the others, and that measurement of only one-or a number of tests would give a useful estimate of future cardiovascular risk. In a world where effective intervention to prevent cardiovascular disease is increasingly available but expensive, effective targeting might maximise the benefit to patients whose cardiovascular risk may be underestimated by conventional risk stratification.
Objectives

Primary
(1) To assess the value of autonomic function testing (baroreflex sensitivity and heart rate variability) as predictors of cardiac outcome (fatal and non-fatal myocardial infarction) in patients with essential hypertension and multiple risk factors for coronary disease.
(2) To compare the effects of the standard antihypertensive regimen (beta-blocker based + a diuretic if necessary) with a calcium channel blocker-based regimen (amlodipine based + an angiotensin-converting enzyme (ACE) inhibitor if necessary) on autonomic function.
Secondary
(1) To compare the effect of atorvastatin lipidlowering therapy vs placebo on autonomic function and vascular compliance over a prolonged period (2 years). Increased low-density lipoprotein (LDL) cholesterol reduces endothelial function and hence nitric oxide (NO) production and so atorvastatin might increase vessel compliance and so increase baroreflex sensitivity.
(2) To look for an interaction between autonomic function and the blood pressure response to antihypertensive therapy with the standard antihypertensive regimen (beta-blocker based ± diuretic) or the calcium channel blocker-based regimen (amlodipine ± ACE inhibitor).
(3) To assess the value of autonomic function testing with baroreflex function and heart rate variability as predictors of fatal and non-fatal stroke.
(4) To assess the value of autonomic function testing with baroreflex function and heart rate variability, as predictors of total cardiovascular mortality.
(5) To assess the value of autonomic function testing with baroreflex function and heart rate variability, as predictors of all cardiovascular events and procedures (morbidity and mortality) and on allcause mortality.
(6) To compare the effect on health care costs of statin treatment in high-risk hypertensives with and without cardiac risk stratification by autonomic function testing.
Tertiary
To look for an interaction between level of baroreflex function and heart rate variability as predictors of cardiovascular outcome during antihypertensive therapy with either the standard antihypertensive regimen (beta-blocker based + a diuretic if necessary) with a calcium channel blocker-based regimen (amlodipine based + an ACE inhibitor if necessary).
Methods
Prospective Randomised Open Blinded Endpoints (PROBE), 2 × 2 factorial trial of two antihypertensive regimens and of a statin vs placebo (the latter comparison is double-blind).
Baroreflex sensitivity measurement and monitoring of heart rate variability will be performed when blood pressure has achieved ASCOT target levels at the 6 month, 1 year or 1.5 year visit, and will be repeated after 2 further years of treatment for hypertension ± statin. (Standard ASCOT follow-up Ϸ5 years (or when pre-specified number of endpoints occur).)
Heart rate variability will be performed as follows: simultaneous measurements of; ECG, respiration (respitrace, pecalibrated against a pneumotach), non-invasive blood pressure (Colin/Sphygmocor BP monitor), CO2 end-tidal, SaO2 (pulse oximetry) will be made during; spontaneous breathing (baseline) (5 min), controlled breathing at 15 breaths/min (3 min), controlled breathing at 6 breaths/min (3 min), rebreathing into a closed circuit with a scrubbing circuit (10 min).
This will allow the following data to be obtained: sympatho-vagal balance on the heart, the effect of slow breathing on blood pressure and baroreflex, an estimate of the hypoxic ventilatory drive and an alternative estimate of the arterial baroreflex (by sequence method and/or 'alpha-angle'). The predetermined protocol avoids the problems of the degree of subject activity altering heart rate variability. 8 Carotid sinus baroreceptor reflexes will be assessed using sinusoidal neck suction applied around the neck of the supine subject. 9 The frequency of the sinusoidal suction will be: (1) six cycles per min (for 2 min), and (2) around 12 cycles per min (for 2 min), a frequency close to, but not at, respiratory frequency (which is maintained at 15 breaths per min by training the subject to follow a sine wave on a monitor screen). Thus separating respiratory and baroreceptor effects on spectral analysis of RR interval changes and allows evaluation of baroreflex sympathetic modulation of the vessels. Baroreflex testing using the neck suction method can comfortably be performed in 30 min in our hands.
Factors known to influence baroreflex sensitivity, such as age, blood pressure and beta-blocker therapy will be recorded.
Echocardiography for measurement of left ventricular wall thickness, and estimation of left ventricular function will be performed close to the time of testing (Figure 1) .
A total of 1000 patients will be recruited from a single centre over 18 months, assuming a 6.35% cumulative cardiac end point rate (non-fatal MI and fatal coronary heart disease (CHD)), then 62 events would be expected over the 5-year follow-up phase of the study. The precise power calculation is difficult because the baroreflex sensitivity is reduced by hypertension and with increasing age, and so the sensitivity of the study population will be reduced overall, reducing the power of the study compared with post-MI studies. ATRAMI found a very strong association between combined depressed baroreflex sensitivity and heart rate variability and cardiovascular end points, and so was considerably overpowered using 1200 patients. 4 . The study of Farrell and colleagues in patients after MI, studied 122 patients and observed 10 arrhythmic events in 1-year follow-up. The baroreflex sensitivities in this study (7.8 ms/mm Hg (s.d. 4.5) for those without end points, and 1.7 ms/mm Hg (s.d. 1.5)) were much more widely separated than is likely to be possible in the ASCOT hypertensive population; this is the reason for pre-stratification by age.
Patients will only be eligible for CARAT when their blood pressure has achieved study target levels, or at 1.5 years, whichever is the sooner. There is obviously a trade-off between including as many patients as possible (to enhance the power of end point discrimination) and the aim of getting a population with relatively homogeneous blood pressure levels (to reduce confounding).
Journal of Human Hypertension
Discussion
The design of ASCOT means that there is no placebo run-in phase, and however desirable, we suggest that the imposition of a placebo-run-in period would be a major variation on the main ASCOT protocol, and could cause significant problems for dovetailing the sub-study into ASCOT. We will, therefore study patients when their blood pressure reaches study targets or after a given period. Other confounding influences on baroreflex sensitivity apart from blood pressure level might include betaadrenoceptor blockade. Any effect of beta-blocker therapy on baroreflex function on the study of patients at the time of the first autonomic function test will not be larger than was encountered in the ATRAMI study, 4 when many of the patients postmyocardial infarct were beta-blocked at the time of baroreflex testing, and in older patients the effect of beta-blockers on baroreflex sensitivity is small.
The opportunity of a large multicentre outcome study like ASCOT should facilitate studies on pathophysiology and on predictors of outcome. Baroreceptor reflexes and autonomic tone are one of a number of promising risk predictors which might add considerably to conventional 'Framingham' type risk factors such as blood pressure, total-to-HDL cholesterol level, smoking etc. Collaboration between groups looking at pulse wave velocity (Williams and others, this issue) and baroreceptor reflexes, for example, in the same group of patients, would give invaluable extra insight as to the relative predictive value of some of these methods.
The East London and the City Health Authority Ethics Committee has approved the sub-study.
